New drug aims to shrink heart plaque in australian trial

NCT ID NCT06700720

Recruiting now Disease control Sponsor: Beijing Inno Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called YN001 in people with coronary atherosclerosis (hardening of the arteries in the heart). The goal is to see if YN001 can reduce plaque buildup in the arteries when added to standard care. About 24 adults in Australia with at least one blocked artery will receive the drug intravenously. The study focuses on safety and changes in plaque seen on CT scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE CORONARY ATHEROSCLEROTIC DISEASE

Contacts and locations

Locations

Albury Wodonga Private Hospital
RECRUITING

Albury, New South Wales, 1125, Australia
Altona Clinical Research
RECRUITING

Melbourne, Victoria, 3025, Australia
Canberra Hospital
RECRUITING

Canberra, Australian Capital Territory, Australia
Core Research Group Pty Ltd
WITHDRAWN

Milton, Queesland, Australia
John Flynn Private Hospital
NOT_YET_RECRUITING

Tugun, Australia
Peninsula Heart Centre
RECRUITING

Melbourne, Victoria, 3199, Australia
Sunshine Coast University Private Hospital
RECRUITING

Birtinya, Queensland, 4575, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.